Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Date of Filing: June 22, 2026
This filing incorporates by reference the first three paragraphs of a press release dated June 22, 2026, regarding the publication of a peer-reviewed scientific article.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on scientific developments rather than financial performance.
Material Changes
Scientific Development: Can-Fite Biopharma Ltd. published a peer-reviewed scientific article demonstrating the broad therapeutic potential of its compounds, Piclidenoson and Namodenoson.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the validation of the company's therapeutic candidates through peer-reviewed publication.
Risks and Contingencies: The filing text does not provide specific details regarding risks, contingencies, or unusual items beyond the standard incorporation of the press release.
Investor Verification Checklist
- Verify the full text of the peer-reviewed scientific article referenced in the press release (Exhibit 99.1).
- Confirm the specific therapeutic indications and data presented for Piclidenoson and Namodenoson.
- Review the company's most recent Form 20-F for current financial status, as this 6-K contains no financial data.